Literature DB >> 29925412

Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.

Isabelle Bos¹, Frans R Verhey², Inez H G B Ramakers², Heidi I L Jacobs², Hilkka Soininen^3,4, Yvonne Freund-Levi⁵, Harald Hampel^6,7, Magda Tsolaki⁸, Åsa K Wallin⁹, Mark A van Buchem¹⁰, Ania Oleksik¹¹, Marcel M Verbeek¹², Marcel Olde Rikkert¹³, Wiesje M van der Flier¹⁴, Philip Scheltens¹⁴, Pauline Aalten², Pieter Jelle Visser^2,14, Stephanie J B Vos².

Abstract

Upon publication of this article [1], it was noticed that there were some inconsistencies in Tables 1, 2 and 3. Some of the superscript letters were incorrectly assigned. Please see below the correct tables.

Entities: Chemical

Year: 2018 PMID： 29925412 PMCID： PMC6011342 DOI： 10.1186/s13195-018-0391-x

Source DB: PubMed Journal: Alzheimers Res Ther Impact factor: 6.982

Correction

Table 1

Comparisons of baseline and follow-up characteristics by Aβ and WMH status

	Aβ- WMH-	Aβ- WMH+	Aβ + WMH-	Aβ + WMH+
	n = 140	n = 39	n = 63	n = 29
Baseline characteristics
Age	61.7 (8.3)^B,C,D	71.3 (7.7)^A,C	66.7 (7.8)^A,B,D	74.1 (5.0)^A,C
Female, n	94 (67)^C	23 (59)	32 (51)^A	16 (55)
Education in years	10.9 (3.1)	11.9 (3.3)	11.1 (3.1)	10.3 (2.9)
Hypertension, n^*	43 (34)	9 (25)	15 (25)	9 (32)
Obesity, n^*	15 (14)	3 (11)	4 (8)	4 (21)
Diabetes, n^*	16 (21)	3 (15)	3 (7)	5 (28)
APOE-ε4 carrier, n^*	33 (51)^B	5 (24)^A,C,D	29 (62)^B	10 (56)^B
Diagnosis MCI, n	70 (50)^D	21 (54)^D	40 (64)	22 (76)^A,B
amnestic MCI (% within MCI group)	40 (57)	15 (71)	27 (68)	17 (77)
non-amnestic MCI (% within MCI group)	30 (43)	6 (29)	13 (33)	5 (23)
CSF Aβ 1–42, pg/ml	973.6 (312.0)^C,D	885.0 (242.0)^C,D	404.3 (102.6)^A,B	419.3 (97.2)^A,B
White matter hyperintensities^†	0.7 (0.5)^B,D	2.3 (0.4)^A,C	0.8 (0.4)^B,D	2.4 (0.5)^A,C
Follow-up characteristics
Follow-up time	2.1 (1.5)	2.2 (1.3)	2.1 (1.2)	2.4 (1.2)
Time to progression to dementia	1.3 (0.5)^B	2.0 (0.7)^A	1.7 (0.7)	2.1 (1.2)
Progression to dementia, n	8 (6)^B,C,D	9 (23)^A	18 (29)^A	11 (38)^A
- AD-type dementia, n	2 (1)^B,C,D	7 (18)^A	18 (29)^A	10 (35)^A
- Vascular dementia, n	0 (0)	2 (5)	0 (0)	1 (3)
- Frontotemporal dementia, n	4 (3)	0 (0)	0 (0)	0 (0)
- Lewy Body dementia, n	1 (1)	0 (0)	0 (0)	0 (0)
- Dementia with unknown etiology, n	1 (1)	0 (0)	0 (0)	0 (0)

Results are mean (SD) for continuous variables or frequency (%). Hypertension, obesity, diabetes and APOE ε4 genotype were only available in a subgroup of the sample

Abbreviations: Aβ amyloid-beta, AD Alzheimer’s disease, APOE Apolipoprotein E, MCI mild cognitive impairment

†WMH measured by the Fazekas scale, range 0–3

Ap < 0.05 compared to Aβ- WMH-

Bp < 0.05 compared to Aβ- WMH+

Cp < 0.05 compared to Aβ + WMH-

Dp < 0.05 compared to Aβ + WMH+

Table 2

Values of neurodegenerative markers by Aβ/WMH groups

	Aβ- WMH-	Aβ- WMH+	Aβ + WMH-	Aβ + WMH+
Neurodegeneration markers	n = 140	n = 39	n = 63	n = 29
MTA score	1.2 (1.2)^B,C,D	2.6 (1.6)^A,D	2.1 (1.6)^A,D	3.4 (1.8)^A,B,C
MTA abnormal, n	62 (45)^B,C,D	32 (82)^A	41 (67)^A,D	26 (93)^A,C
P-tau, pg/ml	54.5 (27.7)^C	63.2 (29.3)	77.0 (56.3)^A	65.2 (38.2)
P-tau abnormal, n	53 (38)^C	22 (58)	45 (71)^A	15 (52)
T-tau, pg/ml	314.7 (202.0)^B,C,D	438.4 (248.0)^A	499.3 (413.8)^A	426.2 (275.2)^A
T-tau abnormal, n	36 (26)^B,C,D	20 (53)^A	36 (57)^A	14 (48)^A

Results are mean (SD) and number (%). All analyses were adjusted for study, baseline diagnosis and demographics

Abbreviations: Aβ amyloid-beta, MTA medial temporal lobe atrophy, P-tau phosphorylated tau, T-tau Total tau, WMH white matter hyperintensities

Ap < 0.05 compared to Aβ- WMH-

Bp < 0.05 compared to Aβ- WMH+.

Cp < 0.05 compared to Aβ + WMH-.

Dp < 0.05 compared to Aβ + WMH+.

Table 3

Cognitive performance and decline by Aβ/WMH groups

		Aβ- WMH-	Aβ- WMH+	Aβ + WMH-	Aβ + WMH+
MMSE^*	n	140	39	62	27
	Baseline	27.79 (27.39, 28.19)	27.52 (26.83, 28.21)	27.20 (26.62, 27.78)	27.40 (26.54, 28.25)
	Slope	−0.01 (− 0.15, 0.12)	− 0.29 (− 0.55, − 0.02)	−0.22 (− 0.44, − 0.01)	− 0.31 (− 0.62, 0.00)
Memory delayed recall z-score	n	133	37	58	27
	Baseline	−0.48 (− 0.72, − 0.24)^B,C,D	−1.04 (− 1.48, − 0.61)^A	−1.04 (− 1.41, − 0.68)^A	−1.33 (− 1.86, − 0.80)^A
	Slope	0.05 (− 0.03, 0.13)	0.02 (− 0.12, 0.17)	0.02 (− 0.11, 0.14)	−0.07 (− 0.24, 0.09)
Executive functioning z-score	n	130	37	60	24
	Baseline	−0.48 (− 0.76, − 0.21)	−0.41 (− 0.92, 0.09)	−0.78 (− 1.18, − 0.37)	−1.12 (− 1.73, − 0.50)
	Slope	0.06 (− 0.02, 0.13)	−0.00 (− 0.15, 0.15)	−0.03 (− 0.16, 0.10)	−0.04 (− 0.23, 0.15)

Results are mean (95% confidence interval). Bold slope estimates = p < 0.05. All analyses were adjusted for study. The analyses on MMSE scores were also corrected for demographics and baseline diagnosis

Abbreviations: Aβ amyloid-beta, MMSE mini mental state examination, WMH white matter Hyperintensities

Ap < 0.05 compared to Aβ- WMH-

Bp < 0.05 compared to Aβ- WMH+.

Cp < 0.05 compared to Aβ + WMH-.

Dp < 0.05 compared to Aβ + WMH+.

Comparisons of baseline and follow-up characteristics by Aβ and WMH status Results are mean (SD) for continuous variables or frequency (%). Hypertension, obesity, diabetes and APOE ε4 genotype were only available in a subgroup of the sample Abbreviations: Aβ amyloid-beta, AD Alzheimer’s disease, APOE Apolipoprotein E, MCI mild cognitive impairment †WMH measured by the Fazekas scale, range 0–3 Ap < 0.05 compared to Aβ- WMH- Bp < 0.05 compared to Aβ- WMH+ Cp < 0.05 compared to Aβ + WMH- Dp < 0.05 compared to Aβ + WMH+ Values of neurodegenerative markers by Aβ/WMH groups Results are mean (SD) and number (%). All analyses were adjusted for study, baseline diagnosis and demographics Abbreviations: Aβ amyloid-beta, MTA medial temporal lobe atrophy, P-tau phosphorylated tau, T-tau Total tau, WMH white matter hyperintensities Ap < 0.05 compared to Aβ- WMH- Bp < 0.05 compared to Aβ- WMH+. Cp < 0.05 compared to Aβ + WMH-. Dp < 0.05 compared to Aβ + WMH+. Cognitive performance and decline by Aβ/WMH groups Results are mean (95% confidence interval). Bold slope estimates = p < 0.05. All analyses were adjusted for study. The analyses on MMSE scores were also corrected for demographics and baseline diagnosis Abbreviations: Aβ amyloid-beta, MMSE mini mental state examination, WMH white matter Hyperintensities Ap < 0.05 compared to Aβ- WMH- Bp < 0.05 compared to Aβ- WMH+. Cp < 0.05 compared to Aβ + WMH-. Dp < 0.05 compared to Aβ + WMH+.

1 in total

1. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.

Authors: Isabelle Bos; Frans R Verhey; Inez H G B Ramakers; Heidi I L Jacobs; Hilkka Soininen; Yvonne Freund-Levi; Harald Hampel; Magda Tsolaki; Åsa K Wallin; Mark A van Buchem; Ania Oleksik; Marcel M Verbeek; Marcel Olde Rikkert; Wiesje M van der Flier; Philip Scheltens; Pauline Aalten; Pieter Jelle Visser; Stephanie J B Vos
Journal: Alzheimers Res Ther Date: 2017-12-29 Impact factor: 6.982

1 in total

1. White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study.

Authors: Nienke Legdeur; Pieter Jelle Visser; Davis C Woodworth; Majon Muller; Evan Fletcher; Pauline Maillard; Philip Scheltens; Charles DeCarli; Claudia H Kawas; María M Corrada
Journal: J Am Geriatr Soc Date: 2019-06-06 Impact factor: 5.562

1 in total